REFERENCES

• McMahonFJ.InselTR.Pharmacogenomics and personalized medicine in neuropsychiatry.Neuron.20127477377622681682
   PubMed Web of Science ®Google Scholar
• VelliganDl.WeidenPJ.SajatovicM.et alStrategies for addressing adherence problems in patintserious and persistent mental illness: recommendations from the expert consensus guidelines.J Psychiatr Pract.20101630632420859108
   PubMed Web of Science ®Google Scholar
• AuffrayC.HoodL.Editorial: Systems biology and personalized medicine - the future is now.Biotechnol J.2012793893922887882
   PubMed Web of Science ®Google Scholar
• DrozdaK.MullerDJ.BishopJR.Pharmacogenomic testing for neuropsychiatry drugs: current status of drug labeling, guidelines for using genetic information, and test options.Pharmacotherapy.2014341668424523097
   PubMed Web of Science ®Google Scholar
• HoeheMR.KroslakT.Genetic variation and pharmacogenomics: concepts, facts, and challenges.Dialogues Clin Neurosci.2004652522033504
   PubMedGoogle Scholar
• WacholderS.Population risk measures.Epidemiol.200516 594
   PubMed Web of Science ®Google Scholar
• HardyJ.Genetic analysis of pathways to Parkinson disease.Neuron.20106820120620955928
   PubMed Web of Science ®Google Scholar
• GottesmanO.KuivaniemiH.TrompG.et alThe Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future.Genet Med.20131576177123743551
   PubMed Web of Science ®Google Scholar
• SiontisGCM.TzoulakiI.loannidisJPA.Predicting death: an empirical evaluation of predictive tools for mortality.Arch Intern Med.20111711721172621788535
   PubMedGoogle Scholar
• FreedmanRA.WinerEP.Adjuvant therapy for postmenopausal women with endocrine-sensitive breast cancer.Breast.201019697520034796
   PubMed Web of Science ®Google Scholar
• Ferrantedi Ruffano L.HydeCJ.McCafferyKJ.BossuytPMM.DeeksJJ.Assessing the value of diagnostic tests: a framework for designing and evaluating trials.BMJ.2012344 e686
   PubMedGoogle Scholar
• Receiver Operating Characteristic Curve. Available at: http://www. adscience.eu/uploads/ckfiles/files/html_files/StatEL/statel_ROC_ curve, htm. Accessed October 2014
   Google Scholar
• AldousSJ.RichardsM.CullenL.TroughtonR.ThanM.Diagnostic and prognostic utility of early measurement with high-sensitivity troponin T assay in patients presenting with chest pain.Can Med Assoc J.2012184e260e26822291171
   PubMed Web of Science ®Google Scholar
• WacholderS.Clinical utility in evaluation of risk models.Am J Epidemiol.201217649549622875758
   PubMed Web of Science ®Google Scholar
• RemboldCM.Number needed to screen: development of a statistic for disease screening.BMJ.19983173073129685274
   PubMedGoogle Scholar
• WalshBT.SeidmanSN.SyskoR.GouldM.Placebo response in studies of major depression: variable, substantial, and growing.JAMA.20022871840184711939870
   PubMed Web of Science ®Google Scholar
• Jane-witD.HorwitzRl.ConcatoJ.Variation in results from randomized, controlled trials: stochastic or systematic?J Clin Epidemiol.201063566319740624
   PubMed Web of Science ®Google Scholar
• WacholderS.Design issues in case-control studies.Stat Methods Med Res.199542933098745128
   PubMedGoogle Scholar
• WacholderS.Bias in full cohort and nested case-control studies?Epidemiol.200920339340
   PubMed Web of Science ®Google Scholar
• TzoulakiI.LiberopoulosG.loannidisJPA.Assessment of claims of improved prediction beyond the Framingham risk score.JAMA.20093022345235219952321
   PubMed Web of Science ®Google Scholar
• KraftP.Curses-winner's and otherwise-in genetic epidemiology.Epidemiol.200819649651
   PubMed Web of Science ®Google Scholar
• XiaoR.BoehnkeM.Quantifying and correcting for the winner's curse in genetic association studies.Genet Epidemiol.20093345346219140131
   PubMed Web of Science ®Google Scholar
• ZollnerS.PritchardJK.Overcoming the winner's curse: estimating penetrance parameters from case-control data.Am J Hum Genet.20078060561517357068
   PubMed Web of Science ®Google Scholar
• loannidisJPA.To replicate or not to replicate: the case of pharmacogenetic studies: have pharmacogenomics failed, or do they just need larger-scale evidence and more replication?Ore Cardiovasc Genet.20136413418
   PubMedGoogle Scholar
• CohenRM.GreenbergJM.IsHakWW.Incorporating multidimensional patient-reported outcomes of symptom severity, functioning, and quality of life in the Individual Burden of Illness Index for Depression to measure treatment impact and recovery in MDD.JAMA Psychiatry.20137034335023303512
   PubMed Web of Science ®Google Scholar
• KatzAJ.DusetzinaSB.FarleyJF.et alDistressing adverse events after antidepressant switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial: influence of adverse events during initial treatment with citalopram on development of subsequent adverse events with an alternative antidepressant.Pharmacotherapy.20123223424322392456
   PubMed Web of Science ®Google Scholar
• FavaM.RushAJ.TrivediMH.et alBackground and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study.Psychiatr Clin North Am.20032645749412778843
   PubMed Web of Science ®Google Scholar
• StroupTS.McEvoyJP.SwartzMS.et alThe National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.Schizophr Bull.200329153112908658
   PubMed Web of Science ®Google Scholar
• DeckersbachT.PetersAT.SylviaL.et alDo comorbid anxiety disorders moderate the effects of psychotherapy for bipolar disorder? Results from STEP-BD.Am J Psychiatry.201417117818624077657
   PubMed Web of Science ®Google Scholar
• FolsteinMF.FolsteinSE.McHughPR.“Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician.J Psychiatr Res.1975121891981202204
   PubMed Web of Science ®Google Scholar
• NortonJC.The Trail Making Test and Bender Background Interference Procedure as screening devices.J Clin Psychol.197834916922711883
   PubMed Web of Science ®Google Scholar
• EisnerE.DrakeR.BarrowcloughC.Assessing early signs of relapse in psychosis: review and future directions.Clin Psychol Rev.20133363765323628908
   PubMed Web of Science ®Google Scholar
• IshakWW.GreenbergJM.CohenRM.Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the Individual Burden of Illness Index for Depression (IBI-D).J Affect Disord.2013151596523790554
   PubMed Web of Science ®Google Scholar
• GrofP.DuffyA.CavazzoniP.et alIs response to prophylactic lithium a familial trait?J Clin Psychiatry.20026394294712416605
   PubMed Web of Science ®Google Scholar
• McGrathLM.CornellsMC.LeePH.et alGenetic predictors of risk and resilience in psychiatric disorders: a cross-disorder genome-wide association study of functional impairment in major depressive disorder, bipolar disorder, and schizophrenia.Am J Med Genet Part B Neuropsychiatr Genet.2013162B779788
   PubMedGoogle Scholar
• SuzukiT.UchidaH.WatanabeK.KashimaH.Factors associated with response to clozapine in schizophrenia: a review.Psychopharmacol Bull.201144326022506438
   PubMedGoogle Scholar
• AwadAG.Drug therapy in schizophrenia-variability of outcome and prediction of response.Can J Psychiatry.1989347117202572318
   PubMed Web of Science ®Google Scholar
• KleindienstN.EngelR.GreilW.Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders.Bipolar Disord.2005740441716176433
   PubMed Web of Science ®Google Scholar
• PeturssonH.Prediction of lithium response.Compr Psychiatry.197920226241376222
   PubMed Web of Science ®Google Scholar
• KempAH.GordonE.RushAJ.WilliamsLM.Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures.CNS Spectr.2008131066108619179943
   PubMed Web of Science ®Google Scholar
• BennabiD.VandelP.PapaxanthisC.PozzoT.HaffenE.Psychomotor retardation in depression: a systematic review of diagnostic, pathophysiologic, and therapeutic implications.BioMed Res Int.20132013158746
   Web of Science ®Google Scholar
• PerlisRH.UherR.OstacherM.et alAssociation between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder.Arch Gen Psychiatry.20116835136021135313
   PubMed Web of Science ®Google Scholar
• SungSC.WisniewskiSR.BalasubramaniGK.et alDoes early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report.Psychol Med.20134394596023228340
   PubMed Web of Science ®Google Scholar
• KozelFA.TrivediMH.WisniewskiSR.et alTreatment outcomes for older depressed patients with earlier versus late onset of first depressive episode: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report.Am J Geriatr Psychiatry.200816586418165462
   PubMed Web of Science ®Google Scholar
• PerlisRH.DennehyEB.MiklowitzDJ.et alRetrospective age at onset of bipolar disorder and outcome during two-year follow-up: results from the STEP-BD study.Bipolar Disord.20091139140019500092
   PubMed Web of Science ®Google Scholar
• ZisookS.LesserI.StewartJW.et alEffect of age at onset on the course of major depressive disorder.Am J Psychiatry.20071641539154617898345
   PubMed Web of Science ®Google Scholar
• FournierJC.DeRubeisRJ.HollonSD.et alAntidepressant drug effects and depression severity: a patient-level meta-analysis.JAMA.2010303475320051569
   PubMed Web of Science ®Google Scholar
• KaneJM.CorrellCU.Pharmacologic treatment of schizophrenia.Dialogues Clin Neurosci.20101234535720954430
   PubMedGoogle Scholar
• CuthbertBN.KozakMJ.Constructing constructs for psychopathology: the NIMH research domain criteria.J Abnorm Psychol.201312292893724016027
   PubMed Web of Science ®Google Scholar
• HaganJJ.JonesDNC.Predicting drug efficacy for cognitive deficits in schizophrenia.Schizophr Bull.20053183085316177277
   PubMed Web of Science ®Google Scholar
• HarveyPD.BowieCR.Cognitive enhancement in schizophrenia: pharmacological and cognitive remediation approaches.Psychiatr Clin North Am.20123568369822929873
   PubMed Web of Science ®Google Scholar
• SarfatiY.Hardy-BayleM-C.Could cognitive vulnerability identify high-risk subjects for schizophrenia?Am J Med Genet.200211489389712457382
   PubMed Web of Science ®Google Scholar
• MeltzerHY.McGurkSR.The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.Schizophr Bull.19992523325510416729
   PubMed Web of Science ®Google Scholar
• MurphyEJ.KassemL.ChemerinskiA.RushAJ.LajeG.McMahonFJ.Retention and attrition among African Americans in the STAR*D study: what causes research volunteers to stay or stray?Depress Anxiety.2013301137114423723044
   PubMed Web of Science ®Google Scholar
• KerberKB.WisniewskiSR.LutherJF.et alEffects of heart disease on depression treatment: results from the COMED study.Gen Hosp Psychiatry.201234243422001552
   PubMed Web of Science ®Google Scholar
• HedayatiSS.MinhajuddinAT.AfsharM.TotoRD.TrivediMH.RushAJ.Association between major depressive episodes in patients with chronic kidney disease and initiation of dialysis, hospitalization, or death.JAMA.20103031946195320483971
   PubMed Web of Science ®Google Scholar
• BryanC.SongerT.BrooksMM.et alThe impact of diabetes on depression treatment outcomes.Gen Hosp Psychiatry.201032334120114126
   PubMed Web of Science ®Google Scholar
• GollanJK.FavaM.KurianB.et alWhat are the clinical implications of new onset or worsening anxiety during the first two weeks of SSRI treatment for depression?Depress Anxiety.2012299410122147631
   PubMed Web of Science ®Google Scholar
• DavisLL.PilkintonP.WisniewskiSR.et alEffect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial.Depress Anxiety.20122911112222495941
   PubMed Web of Science ®Google Scholar
• DavisLL.WisniewskiSR.HowlandRH.et alDoes comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes.Drug Alcohol Depend.201010716117019945804
   PubMed Web of Science ®Google Scholar
• LiXYuK.MeiSet alHLA-B*1502 increases the risk of phenytoin or lamotrigine induced Stevens-Johnson Syndrome/toxic epidermal necrolysis: Evidence from a meta-analysis of nine case-control studies.Drug Res Stuttg.2014 epub May 28 2014
   Google Scholar
• GrattenJ.WrayNR.KellerMC.VisscherPM.Large-scale genomics unveils the genetic architecture of psychiatric disorders.Nat Neurosci.20141778279024866044
   PubMed Web of Science ®Google Scholar
• Le-NiculescuH.PatelSD.BhatM.et alConvergent functional genomics of genome-wide association data for bipolar disorder: comprehensive identification of candidate genes, pathways and mechanisms.Am J Med Genet Part B Neuropsychiatr Genet.2009150B155181
   PubMed Web of Science ®Google Scholar
• Li-Pook-ThanJ.SnyderM.iPOP goes the world: integrated personalized Omics profiling and the road toward improved health care.Chem Biol.20132066066623706632
   PubMedGoogle Scholar
• HoodL.TianQ.Systems approaches to biology and disease enable translational systems medicine.Genomics Proteomics Bioinformatics.20121018118523084773
   PubMedGoogle Scholar
• BoyleAP.HongEL.HariharanM.et alAnnotation of functional variation in personal genomes using RegulomeDB.Genome Res.2012221790179722955989
   PubMed Web of Science ®Google Scholar
• JanssensACJW.loannidisJPA.van DuijnCM.LittleJ.KhouryMJ.Strengthening the reporting of genetic risk prediction studies: the GRIPS statement.Genet Med.20111345345621502867
   PubMed Web of Science ®Google Scholar
• loannidisJPA.Personalized genetic prediction: too limited, too expensive, or too soon?Ann Intern Med.200915013914119153414
   PubMed Web of Science ®Google Scholar
• GreshakeB.BayerPE.RauschH.RedaJ.openSNP-a crowdsourced web resource for personal genomics.PLoS One.20149e8920424647222
   PubMed Web of Science ®Google Scholar
• GaoY.GalanteM.El-MallakhJ.et alBDNF expression in lymphoblastoid cell lines carrying BDNF SNPs associated with bipolar disorder.Psychiatr Genet.20122225325522517381
   PubMed Web of Science ®Google Scholar
• EvansKC.DoughertyDD.PollackMH.RauchSL.Using neuroimaging to predict treatment response in mood and anxiety disorders.Ann Clin Psychiatry.200618334216517451
   PubMedGoogle Scholar
• FuCHY.CostafredaSG.Neuroimaging-based biomarkers in psychiatry: clinical opportunities of a paradigm shift.Can J Psychiatry.20135849950824099497
   PubMed Web of Science ®Google Scholar
• MacQueenGM.Magnetic resonance imaging and prediction of outcome in patients with major depressive disorder.J Psychiatry Neurosci.20093434334919721844
   PubMed Web of Science ®Google Scholar
• KozelFA.RaoU.LuH.et alFunctional connectivity of brain structures correlates with treatment outcome in major depressive disorder.Front Psychiatry.20112721556277
   PubMedGoogle Scholar
• TomasikJ.RahmouneH.GuestPC.BahnS.Neuroimmune biomarkers in schizophrenia.Schizophr Res.2014 epub 12 August
   Google Scholar
• JaworskaN.ProtznerA.Electrocortical features of depression and their clinical utility in assessing antidepressant treatment outcome.Can J Psychiatry Rev Can Psychiatr.201358509514
   PubMed Web of Science ®Google Scholar
• CookIA.HunterAM.GilmerWS.et alQuantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the Biomarkers for Rapid Identification of Treatment Effectiveness in Major Depression (BRITE-MD) trial. JClin Psychiatry.2013745156
   PubMed Web of Science ®Google Scholar
• GuestPC.Martins-de-SouzaD.SchwarzE.et alProteomic profiling in schizophrenia: enabling stratification for more effective treatment. Genome Med.2013525
   Google Scholar
• BrennandKJ.SimoneA.JouJ.et alModelling schizophrenia using human induced pluripotent stem cells.Nature.201147322122521490598
   PubMed Web of Science ®Google Scholar
• WenZ.NguyenHN.GuoZ.et alSynaptic dysregulation in a human iPS cell model of mental disorders.Nature.201451541441825132547
   PubMed Web of Science ®Google Scholar
• TrivediMH.Modeling predictors, moderators and mediators of treatment outcome and resistance in depression.Biol Psychiatry.2013742423787333
   PubMed Web of Science ®Google Scholar
• LeuchterAF.CookIA.MarangellLB.et alComparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in major depressive disorder: results of the BRITE-MD study.Psychiatry Res.2009 16912413119712979
   PubMed Web of Science ®Google Scholar
• MurphyE.HouL.MaherBS.et alRace, genetic ancestry and response to antidepressant treatment for major depression.Neuropsychopharmacol.20133825982606
   PubMed Web of Science ®Google Scholar
• TomitaT.Yasui-FurukoriN.SatoY.et alSex differences in the prediction of the effectiveness of paroxetine for patients with major depressive disorder identified using a receiver operating characteristic curve analysis for early response.Neuropsychiatr Dis Treat.20141059960624748795
   PubMed Web of Science ®Google Scholar
• KempDE.GanocySJ.BrecherM.et alClinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression.J Affect Disord.201113017117921071096
   PubMed Web of Science ®Google Scholar
• LewisCC.SimonsAD.KimHK.The role of early symptom trajectories and pretreatment variables in predicting treatment response to cognitive behavioral therapy.J Consult Clin Psychol.20128052553422730951
   PubMed Web of Science ®Google Scholar
• DreimullerN.SchlichtKF.WagnerS.et alEarly reactions of brainderived neurotrophic factor in plasma (pBDNF) and outcome to acute antidepressant treatment in patients with Major Depression.Neuropharmacology.20126226426921803060
   PubMed Web of Science ®Google Scholar
• CorrellCU.ZhaoJ.CarsonW.et alEarly antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinicaloutcomes. J Am Acad Child Adolesc Psychiatry.201352689698
   PubMed Web of Science ®Google Scholar
• Stentebjerg-OlesenM.JeppesenP.PagsbergAK.et alEarly nonresponse determined by the clinical global impressions scale predicts poorer outcomes in youth with schizophrenia spectrum disorders naturalistically treated with second-generation antipsychotics.J Child Adolesc Psychopharmacol.20132366567524266529
   PubMed Web of Science ®Google Scholar
• BuitelaarJK.Van derGaag RJ.Swaab-BarneveldH.KuiperM.Prediction of clinical response to methylphenidate in children with attention-deficit hyperactivity disorder.J Am Acad Child Adolesc Psychiatry.199534102510327665441
   PubMed Web of Science ®Google Scholar
• PyeritzRE.The family history: the first genetic test, and still useful after all those years?Genet Med.2012143922237427
   PubMed Web of Science ®Google Scholar
• BergAO.BairdMA.BotkinJR.et alNational Institutes of Health State-of-the-Science Conference Statement: Family History and Improving Health.Ann Intern Med.200915187287719884615
   PubMed Web of Science ®Google Scholar
• DoCB.HindsDA.FranckeU.ErikssonN.Comparison of family history and SNPs for predicting risk of complex disease.PLoS Genet.20128e100297323071447
   PubMed Web of Science ®Google Scholar
• WilsonBJ.QureshiN.SantaguidaP.et alSystematic review: family history in risk assessment for common diseases.Ann Intern Med.200915187888519884616
   PubMed Web of Science ®Google Scholar
• AnanthJ.PecknoldJC.Prediction of lithium response in affective disorders.J Clin Psychiatry.19783995100344305
   PubMed Web of Science ®Google Scholar
• WattendorfDJ.HadleyDW.Family history: the three-generation pedigree.Am Fam Physician.20057244144816100858
   PubMed Web of Science ®Google Scholar
• KendlerKS.Family history information in biomedical research.J Contin Educ Health Prof.20012121522311803766
   PubMedGoogle Scholar